Carbidopa

Generic Name
Carbidopa
Brand Names
Dhivy, Duodopa, Duopa, Lodosyn, Parcopa, Rytary, Sinemet, Stalevo
Drug Type
Small Molecule
Chemical Formula
C10H14N2O4
CAS Number
28860-95-9
Unique Ingredient Identifier
KR87B45RGH
Background

Carbidopa presents a chemical denomination of N-amino-alpha-methyl-3-hydroxy-L-tyrosine monohydrate. It potently inhibits aromatic amino acid decarboxylase (DDC) and due to its chemical properties, it does not cross the blood-brain barrier. Due to its activity, carbidopa is always administered concomitantly with levodopa. An individual formulation containing...

Indication

Carbidopa is indicated with levodopa for the treatment of symptoms of idiopathic Parkinson disease, postencephalitic parkinsonism and symptomatic parkinsonism followed by carbon monoxide or manganese intoxication.

The combination therapy is administered for the reduction of levodopa-driven nausea and vomiting.
...

Associated Conditions
Parkinson's Disease (PD), Parkinsonism post encephalitic, Symptomatic Parkinson Disease, Levodopa-driven nausea and vomiting
Associated Therapies
-
Clinical Trials
Related News

A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma

First Posted Date
2015-12-17
Last Posted Date
2016-06-13
Lead Sponsor
Acorda Therapeutics
Target Recruit Count
25
Registration Number
NCT02633007
Locations
🇺🇸

Site 002, Daytona Beach, Florida, United States

🇺🇸

Site 003, Dallas, Texas, United States

🇺🇸

Site 001, North Dartmouth, Massachusetts, United States

A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults

Phase 1
Completed
Conditions
Smoking
Interventions
Drug: CVT-301
Drug: Carbidopa
First Posted Date
2015-12-17
Last Posted Date
2016-07-14
Lead Sponsor
Acorda Therapeutics
Target Recruit Count
60
Registration Number
NCT02633839
Locations
🇺🇸

Site 001, Daytona Beach, Florida, United States

🇺🇸

Site 002, Dallas, Texas, United States

A Study to Compare Plasma Levels of Levodopa, Carbidopa and Entacapone After TRIGEL or Duodopa Infusion in PD Patients

Phase 1
Completed
Conditions
Parkinson's Disease
Interventions
Drug: TRIGEL
Drug: Duodopa
First Posted Date
2015-05-20
Last Posted Date
2016-05-23
Lead Sponsor
LobSor Pharmaceuticals AB
Target Recruit Count
11
Registration Number
NCT02448914
Locations
🇸🇪

Clinical Trial Consultants AB, Uppsala, Sweden

Efficacy of Co-administration of an NSAID With a Dopamine Agonist In Healthy Subjects

Phase 2
Withdrawn
Conditions
Acute Pain
Interventions
Drug: Placebo
Drug: Naproxen
Drug: Sinemet
First Posted Date
2014-04-17
Last Posted Date
2014-10-10
Lead Sponsor
Northwestern University
Registration Number
NCT02116790

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon

First Posted Date
2012-04-02
Last Posted Date
2015-09-18
Lead Sponsor
Bial - Portela C S.A.
Target Recruit Count
600
Registration Number
NCT01568073
Locations
🇵🇹

Bial - Portela & Cª, S.A., S. Mamede do Coronado, Portugal

High and Low Dose Carbidopa Treatment of Parkinson's Disease

Phase 2
Completed
Conditions
Parkinson's Disease
Interventions
Drug: carbidopa
First Posted Date
2011-07-22
Last Posted Date
2020-01-09
Lead Sponsor
Oregon Health and Science University
Target Recruit Count
14
Registration Number
NCT01399905
Locations
🇺🇸

Oregon Health & Science University, Portland, Oregon, United States

Study To Assess The Clinical Benefit Of Droxidopa And Droxidopa/Carbidopa In Subjects With Fibromyalgia

First Posted Date
2011-03-25
Last Posted Date
2024-02-14
Lead Sponsor
Chelsea Therapeutics
Target Recruit Count
122
Registration Number
NCT01323374
Locations
🇬🇧

MAC UK Neuroscience, Manchester, United Kingdom

🇬🇧

Academic Dept of Rheumatology, Kings College London, London, United Kingdom

🇬🇧

Rheumatology Department, Poole Hospital NHS Trust, Poole, United Kingdom

and more 3 locations

Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens

Phase 2
Completed
Conditions
Parkinson's Disease
Interventions
Drug: Carbidopa
First Posted Date
2011-02-15
Last Posted Date
2011-09-12
Lead Sponsor
Orion Corporation, Orion Pharma
Target Recruit Count
27
Registration Number
NCT01296464
Locations
🇫🇮

ODL Terveys Oy (ODL), Oulu, Finland

🇫🇮

Porin Lääkäritalo, Pori, Finland

🇫🇮

Kanta-Hämeen keskussairaala, Hämeenlinna, Finland

and more 2 locations

Clinical and Economic Impact of Duodopa: Long-term Effectiveness Study in Advanced Parkinson's Disease Patients

First Posted Date
2011-02-08
Last Posted Date
2016-10-11
Lead Sponsor
Poitiers University Hospital
Target Recruit Count
56
Registration Number
NCT01291537
Locations
🇫🇷

Chu de Nice, Nice, France

🇫🇷

Chu Clermont-Ferrand, Clermont-ferrand, France

🇫🇷

CH d'Aix en Provence, Aix en Provence, France

and more 17 locations

A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease Patients

Phase 1
Completed
Conditions
Parkinson's Disease
Interventions
Drug: Saline
Drug: Carbidopa
First Posted Date
2010-10-27
Last Posted Date
2011-12-06
Lead Sponsor
NeuroDerm Ltd.
Target Recruit Count
24
Registration Number
NCT01229332
Locations
🇮🇱

Hadassah Medical Center, Jerusalem, Israel

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy